Literature DB >> 2787295

Risk factors for cervical cancer in Greenland and Denmark: a population-based cross-sectional study.

S K Kjaer1, C Teisen, B J Haugaard, E Lynge, R B Christensen, K A Møller, H Jensen, P Poll, B F Vestergaard, E M de Villiers.   

Abstract

The incidence of cervical cancer in Greenlandic women aged 20-39 years is nearly 6 times higher than in Danish women of the same age. Possible determinants of cervical cancer incidence were investigated in a population-based cross-sectional study. From Nuuk (Greenland) and Nykøbing Falster (Denmark) a sample of 800 women aged 20-39 years was drawn at random. A total of 586 and 661 women were studied in Greenland and Denmark, respectively. All underwent a personal interview. In Greenland, 13% of the women reported first intercourse before the age of 14 in contrast to 3.5% in Denmark, and nearly 85% of the Greenlanders had their sexual debut before the end of the 16th year of age whereas this applied to only 45% of the Danish women. The prevalence of women with 0-1 lifetime sexual partner was 20.4% in Denmark, and only 1.7% in Greenland. In contrast, 53.2% of the Greenlandic women reported more than 20 partners and 22.4% more than 40 partners. The corresponding figures for Denmark were 3.6% and 0.3%, respectively. In Greenland the most common contraceptive method was the use of intra-uterine devices (73.6%), whereas, in Denmark, oral contraceptive use was most frequent (87.9%). Few Greenlanders had ever used "barrier" contraceptives (diaphragm: 1.4%; condom: 18.1%) compared to Denmark (diaphragm: 10.1%; condom: 53.9%). As many as 87.4% were current smokers in Greenland (Denmark: 53.6%) and 5.6% claimed to have never smoked, whereas this applied to 35.3% in Denmark. The indications of a higher sexual activity (multiple partners, early age at first intercourse) in Greenland compared to Denmark are in line with the observed higher rates of sexually transmitted diseases and with the hypothesis that differences in cervical cancer incidence between Greenland and Denmark are determined by aspects of sexual background.

Entities:  

Keywords:  Age Factors; Americas; Barrier Methods; Behavior; Biology; Cancer; Cervical Cancer; Condom; Contraception; Contraceptive Methods; Contraceptive Usage; Cross Sectional Analysis; Demographic Factors; Denmark; Developed Countries; Diseases; Europe; Family Planning; Greenland; Incidence; Marital Status; Measurement; Neoplasms; North America; Northern America; Northern Europe; Nuptiality; Population; Population Characteristics; Prevalence; Research Methodology; Risk Factors; Scandinavia; Sex Behavior; Smoking; Vaginal Barrier Methods; Vaginal Diaphragm

Mesh:

Year:  1989        PMID: 2787295     DOI: 10.1002/ijc.2910440108

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  Human papillomavirus testing in the prevention of cervical cancer.

Authors:  Mark Schiffman; Nicolas Wentzensen; Sholom Wacholder; Walter Kinney; Julia C Gage; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2011-01-31       Impact factor: 13.506

Review 2.  Report of a National Workshop on Screening for Cancer of the Cervix.

Authors:  A B Miller; G Anderson; J Brisson; J Laidlaw; N Le Pitre; P Malcolmson; P Mirwaldt; G Stuart; W Sullivan
Journal:  CMAJ       Date:  1991-11-15       Impact factor: 8.262

Review 3.  Pathobiology of papillomavirus-related cervical diseases: prospects for immunodiagnosis.

Authors:  C P Crum; S Barber; J K Roche
Journal:  Clin Microbiol Rev       Date:  1991-07       Impact factor: 26.132

4.  Women with multiple sexual partners: united states, 1988.

Authors:  S N Seidman; W D Mosher; S O Aral
Journal:  Am J Public Health       Date:  1992-10       Impact factor: 9.308

5.  Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look.

Authors:  S K Kjaer; E M de Villiers; H Cağlayan; E Svare; B J Haugaard; G Engholm; R B Christensen; K A Møller; P Poll; H Jensen
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.